1. | researcher17 | |
2. | lakehome45 | |
3. | ggordon100 | |
4. | SPICKS100 | |
5. | umberjacques |
1. | researcher17 | |
2. | lakehome45 | |
3. | ggordon100 | |
4. | SPICKS100 | |
5. | umberjacques |
1. | umberjacques 10/17/2017 Top Analyst likes it.... |
2. | researcher17 09/25/2017 long haul individuals, long haul. Disregard the reality administration dumped shares a week ago and around 18% prior |
3. | ggordon100 09/25/2017 would you be able to present at a meeting if your organization's stock cost was down just about 20% |
4. | lakehome45 09/25/2017 Hard couple of days |
5. | lakehome45 02/07/2018 Announces updated data from expansion cohorts in a phase 1 trial of cabozantinib in combination with either … |
6. | researcher17 10/17/2017 Positive study results and regulatory news and still could not hold onto gains. Maybe consolidation for a while? {Image} |
7. | lakehome45 10/17/2017 NEWS: Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News |
8. | researcher17 03/15/2018 Company has completed the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug… |
9. | SPICKS100 05/17/2018 Exelixis partner Ipsen |
10. | ggordon100 02/13/2018 Announces results from Phase 2 |